(Total Views: 302)
Posted On: 04/08/2020 11:31:02 AM
Post# of 36566
Q for those with better science knowledge than I have:
Our vaccine science is presented as, and at least to intelligent, non-science experts is perceived to be, better than other approaches (peptides vs RNA, can produce a trillion doses in 3 minutes, safer, can possibly skip to human testing more quickly, vaccine vs treatment etc). Yet we have clearly not hit our stride as far as financing, publicity, and general buy-in from anyone with clout, money, etc.
Frankly, I don’t buy the “small company, OTC, everyone is concentrating on treatment” story as an explanation for our lack of traction. Things are moving at almost unsafe speeds in testing/funding.
And I believe the latest public info points to a definite stall in the China approach.
Someone super-smart in science please help me understand, because I feel like one of these two possibilities is the answer to the question, “Why hasn’t Generex/NGIO made any headway in vaccine funding?”
A). There is some hole in the science that we can’t perceive, due to lack of knowledge or incomplete information, or
. The publicity or presentation of our approach, experience, data, etc. is unconvincing or ineffective.
Constructive thoughts?
Our vaccine science is presented as, and at least to intelligent, non-science experts is perceived to be, better than other approaches (peptides vs RNA, can produce a trillion doses in 3 minutes, safer, can possibly skip to human testing more quickly, vaccine vs treatment etc). Yet we have clearly not hit our stride as far as financing, publicity, and general buy-in from anyone with clout, money, etc.
Frankly, I don’t buy the “small company, OTC, everyone is concentrating on treatment” story as an explanation for our lack of traction. Things are moving at almost unsafe speeds in testing/funding.
And I believe the latest public info points to a definite stall in the China approach.
Someone super-smart in science please help me understand, because I feel like one of these two possibilities is the answer to the question, “Why hasn’t Generex/NGIO made any headway in vaccine funding?”
A). There is some hole in the science that we can’t perceive, due to lack of knowledge or incomplete information, or
. The publicity or presentation of our approach, experience, data, etc. is unconvincing or ineffective. Constructive thoughts?
(2)
(0)
